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Abstract
Background: Methamphetamine (MA) use is a worldwide problem. Abusers can have cognitive
deficits, monoamine reductions, and altered magnetic resonance spectroscopy findings. Animal
models have been used to investigate some of these effects, however many of these experiments
have not examined the impact of MA on the stress response. For example, numerous studies have
demonstrated (+)-MA-induced neurotoxicity and monoamine reductions, however the effects of
MA on other markers that may play a role in neurotoxicity or cell energetics such as glucose,
corticosterone, and/or creatine have received less attention. In this experiment, the effects of a
neurotoxic regimen of (+)-MA (4 doses at 2 h intervals) on brain monoamines, neostriatal GFAP,
plasma corticosterone, creatinine, and glucose, and brain and muscle creatine were evaluated 1, 7,
24, and 72 h after the first dose. In order to compare MA's effects with stress, animals were
subjected to a forced swim test in a temporal pattern similar to MA administration [i.e., (30 min/
session) 4 times at 2 h intervals].
Results: MA increased corticosterone from 1–72 h with a peak 1 h after the first treatment,
whereas glucose was only increased 1 h post-treatment. Neostriatal and hippocampal monoamines
were decreased at 7, 24, and 72 h, with a concurrent increase in GFAP at 72 h. There was no effect
of MA on regional brain creatine, however plasma creatinine was increased during the first 24 h
and decreased by 72 h. As with MA treatment, forced swim increased corticosterone more than
MA initially. Unlike MA, forced swim reduced creatine in the cerebellum with no change in other
brain regions while plasma creatinine was decreased at 1 and 7 h. Glucose in plasma was decreased
at 7 h.
Conclusion: Both MA and forced swim increase demand on energy substrates but in different
ways, and MA has persistent effects on corticosterone that are not attributable to stress alone.
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Background
The psychostimulant methamphetamine (MA) is an
addictive drug that has surged in popularity in the past 15
years. In the United States, 4.4% of 12th graders and
~7.2% of 29–30 year olds reported life-time MA use in
2006 [1,2]. MA intoxication heightens attention and
decreases fatigue, appetite, and anxiety along with stimu-
lating the sympathetic nervous system, resulting in tachy-
cardia, hypertension, diaphoresis, tachypnea, and
hyperthermia [3], symptoms also associated with stressful
situations. Consistent with a stress-like response, MA
exposure also produces elevated cortisol in humans [4]. In
addition, acute MA intoxication often results in increased
serum creatinine, the metabolite of creatine, which may
be due to rhabdomyolysis with acute renal failure [5].
Chronic use of MA produces detrimental alterations in the
brain. For example, reductions of brain monoamines and
associated reuptake transporters are observed in abusers
[3,6,7]. Likewise, magnetic resonance spectroscopy stud-
ies have shown reduced total creatine (α-methyl-guanidi-
noacetic acid) in the basal ganglia after MA exposure in
adults but increased creatine in school-aged children who
were exposed to MA in utero [7]. Concurrent with the var-
ious neurochemical changes that occur following chronic
abuse of MA, various studies have shown that humans
have long-term learning and memory deficits, even after a
period of abstinence. The mechanism(s) underlying the
learning and memory deficits following MA are unknown,
although stress-related pathways may be involved since
increased cortisol [8] has been shown to affect cognitive
function. Furthermore, the creatine system may be
involved in these learning deficits, since it has been shown
that learning and memory are affected by reductions in
creatine in the brain [9].
MA treatment in rats (single-day, 5–10 mg/kg repeated at
2–3 h intervals) produces monoamine and associated
transporter reductions similar to those seen in humans
[10,11]. In addition, MA induces astrogliosis (increased
glial fibrillary acidic protein (GFAP)), argyrophilia, and
Fluoro-Jade staining [12,13], all indicators of neurotoxic-
ity. Similar to humans, corticosterone and adrenocortico-
trophin hormone (ACTH) are elevated after MA exposure
in rats [14,15], although a time course of corticosterone
increase in rats following MA is unknown. MA is also
pyrogenic and at sufficient doses induces hyperthermia.
MA-induced hyperthermia may play a role in the neuro-
toxic effects of the drug [12].
Because of the increased activation of stress-related path-
ways following MA administration and the lack of a more
immediate profile (e.g., between 1–24 h following the
first dose) for these changes, the first objective of this
study was to examine various physiological parameters
during and shortly following MA treatment. Corticoster-
one was selected as a marker of hypothalamic-pituitary-
adrenal (HPA) axis activation, glucose as a marker of
homeostasis, and levels of monoamines in the brain were
assessed because of the well-known effect of MA on these
neurotransmitters. Creatine in the brain in various regions
and creatinine in plasma were assessed because the
human literature demonstrates lasting changes in the cre-
atine system following MA abuse and acute changes in
creatinine during MA intoxication. The creatine system is
a significant source of metabolic energy by providing a
substrate for ATP-regeneration and storage in the brain
[16]. A later time-point following MA (i.e., 72 h) was
added to corroborate previously reported effects on mark-
ers of neurotoxicity, i.e., increased GFAP and decreased
levels of dopamine in the neostriatum [13]. Once a profile
of effects during the first 24 h was established for MA, we
compared that profile to one obtained using forced swim
to determine if MA produced unique effects that were dis-
tinguishable from a stressor. Accordingly, we conducted a
second experiment in which we investigated the effects of
a stressor (forced swim) in an experimental design similar
to that used to investigate the effects of MA.
In order to compare the effects of MA and stress, we
wanted a stressor known to produce a large increase in
corticosterone comparable to that caused by MA. Kirby et
al. [17] showed that forced swim (FS) for 30 min
increased corticosterone immediately following exposure
more than tail pinch, cold, immobilization, or forced
motor activity (rotarod). In addition, FS was selected
because MA-treated animals display hyperactivity during
drug treatment and animals require active movement dur-
ing swimming (whereas animals immobilized or
restrained do not). Forced swim for 30 min has also been
shown to affect the 5-HT system by increasing 5-HT (up to
3 h after the swim) and decreasing 5-HIAA in the striatum




In Experiment 1, animals were given 10 mg/kg MA or an
equivalent volume of saline (SAL), four times on a single
day at 2 h intervals. Two cohorts of animals were used.
Body Temperatures
Body temperatures were collected immediately prior to
MA and every 30 min during and after MA treatment until
2 h following the first dose. There were no differences in
body temperatures among groups prior to drug treatment.
There were significant main effects of Treatment, F(1, 47)
= 63.17, p < 0.0001, and Time (p < 0.0001), as well as the
interaction of Treatment × Time, F(17, 799) = 8.12, p <
0.0001, on post-drug body temperatures. Examination of
the Treatment × Time interaction revealed that animalsBMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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treated with MA began showing hyperthermia relative to
SAL-treated animals beginning ~30 min after the first dose
(p < 0.0001) and this continued for the remainder of the
temperature collection period (30–570 min, p ≤ 0.01; Fig.
1). The decline of body temperature in MA-treated ani-
mals that reached a nadir at 180 min was caused by slight
overcooling of the first cohort of MA-treated animals. The
cooling procedure was used to ensure that animals did not
die because of hyperthermia, but it was insufficient to pro-
tect animals from MA-induced decreases in monoamines
or neurotoxicity. Based on the rapid decrease in tempera-
ture with some of the animals in the first cohort, body
temperatures were monitored more closely and cooling
was discontinued when body temperatures began to
decline in the second cohort. Examination of the outcome
measures, however, revealed no differences between
cooled and non-cooled MA-treated animals, indicating
that this transient temperature reduction did not alter the
effects of MA and succeeded in protecting animals from
hyperthermia-induced death.
Body Weights
In addition to body temperatures, body weights were col-
lected at predetermined time intervals. There were no ini-
tial differences in body weights between treatment groups
(not shown). At 24 h following the first dose, MA-treated
animals weighed significantly less than SAL-treated ani-
mals, F(1, 35) = 7.61, p < 0.01 (not shown). There were
no differences between MA- and SAL-treated animals at 48
or 64 h (not shown).
Corticosterone
Plasma was collected from groups of animals at 1, 7, 24,
and 72 h after the first dose of MA and assessed for corti-
costerone, glucose, and creatinine. Corticosterone levels
were significantly affected by MA treatment. There were
effects of Treatment, F(1, 76) = 73.33, p < 0.0001, Time (p
< 0.0001), and the interaction of Treatment × Time, F (3,
76) = 11.92, p < 0.0001. Examination of the interaction
showed that 1 h after the first dose, corticosterone levels
were increased in MA-treated animals compared to SAL-
treated animals. Corticosterone levels in MA-treated ani-
mals declined thereafter, but remained significantly ele-
vated compared to SAL-treated animals at 7, 24, and 72 h
(Fig. 2A).
Glucose
For levels of glucose in blood, there was a Time main
effect (p < 0.0001), however no main effect of Treatment
was observed. There was also a nearly significant interac-
tion of Treatment × Time, F (3, 76) = 2.63, p = 0.056.
Analysis of the interaction revealed that MA-treated ani-
mals showed increased glucose levels 1 h after the first
dose, but not thereafter (Fig. 3A).
Creatinine
There was a significant interaction of Treatment × Time on
plasma creatinine, F(3, 77) = 5.81, p < 0.002, as well as the
main effect of Time (p < 0.006). Creatinine was
unchanged 1 h following the first dose of MA, however at
7 and 24 h, MA-treated animals showed increased creati-
nine compared to SAL-treated animals (Fig. 4A). At 72 h,
MA-treated animals had decreased creatinine levels com-
pared to SAL-treated animals (Fig. 4A).
Creatine
In addition to the plasma that was collected from groups
of animals at 1, 7, 24, and 72 h after the first dose of MA,
brain regions were also dissected from these animals and
assessed for tissue creatine levels and monoamines. There
were no significant effects of Treatment on creatine levels
in any of the brain regions examined (hippocampus,
neostriatum, prefrontal cortex, or cerebellum; Fig. 4B–E,
respectively). In order to determine if creatine might have
been altered in muscle at any of the time points, the gas-
trocnemius muscle was dissected and assessed for total
creatine. Similar to brain, no effect of MA on creatine lev-
els in muscle at any of the time points examined was
found (Fig. 4F).
Monoamines
In the neostriatum, DA, DOPAC, 5-HT, and 5-HIAA were
affected by Treatment, F(1, 68) = 29.51, 26.36, 44.90, and
12.68, respectively, p < 0.001, and this interacted with
Time, Treatment × Time, for DA, DOPAC, 5-HT, 5-HIAA:
F(3, 68) = 11.98, 2.84, 3.70, and 3.70, respectively, p <
Body temperatures of animals in Experiment 1 (mean ± SEM) Figure 1
Body temperatures of animals in Experiment 1 
(mean ± SEM). No differences in initial temperatures were 
observed (Time = 0); however, MA produced significant 
increases in body temperature during subsequent tempera-
ture collection times. Arrows denote injection times. *p ≤ 
0.05 vs SAL.BMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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0.05. Only DA and 5-HIAA showed a Time main effect (p
< 0.01). Analysis of the interaction revealed that MA-
treated animals showed decreased DA, DOPAC, 5-HT,
and 5-HIAA at 7, 24, and 72 h after the first dose, but not
at 1 h (Fig. 5A–D). For DA, levels at 1 h had a tendency to
be higher in MA-treated animals compared to SAL-treated
(Fig. 5A).
In the hippocampus, there were significant effects of
Treatment, F(1, 68) = 155.67, p < 0.0001, and Time (p <
0.001) for 5-HT, but no interaction. MA-treated animals
showed decreased 5-HT levels compared to SAL-treated
animals at all time points (Fig. 6A). For 5-HIAA, there
were significant effects of Treatment, F(1, 68) = 121.04, p
< 0.0001, and Time (p < 0.0001). There was also an inter-
action of Treatment × Time for 5-HIAA, F(3, 68) = 14.94,
p < 0.0001. MA-treated animals demonstrated decreased
5-HIAA except at 1 h after the first dose (Fig. 6B).
Glial Fibrillary Acidic Protein
GFAP was measured in the neostriatum at 72 h by Western
blot (Fig. 7A) and expressed against actin levels (Fig. 7B)
to verify that the dosing regimen of MA used here pro-
duced neurotoxicity. MA-exposed animals showed signif-
icantly increased GFAP levels compared to SAL-treated
animals, t(5) = -4.63, p < 0.01, which represented a 54%
± 12% increase in GFAP expression from MA treatment.
Values are expressed as percent control (Fig. 7C).
Adrenal and Thymus weights
Since stress and/or high levels of circulating corticoster-
one can influence organ weights, we also collected the
adrenals and thymuses to determine if changes in organ
weights were occurring. The weights of the thymus and
adrenal glands were analyzed for absolute tissue weight
and as a percentage of body weight; for simplicity, only
the percentage of body weight means are presented in
Table 1. There were main effects of Treatment for the abso-
lute weight and percentage of body weight of the thymus,
F(1, 76) = 24.91 and 13.07, respectively, p < 0.001 (Table
1 for percent weight). There was also a main effect of Time
(p < 0.0001), and an interaction of Treatment × Time,
F(3,76) = 2.66, p = 0.05 for absolute values, but not for
percentage of body weight. The effect of MA treatment was
to reduce thymic weight. For the adrenal glands, a main
effect of Treatment was observed for the absolute weight,
F(1, 71) = 7.39, p < 0.01, but not for percentage of body
weight. This effect was attributable to an overall decrease
in adrenal weight in MA-treated animals compared to
SAL-treated controls. There was also a main effect of Time
for both absolute weight and percentage of body weight
(p < 0.01), but no interaction of Treatment × Time (Table
1 for percentage of body weight).
Corticosterone levels in plasma following methamphetamine treatment in Experiment 1 (A) or forced swim in Experiment 2  (B) (mean ± SEM) Figure 2
Corticosterone levels in plasma following methamphetamine treatment in Experiment 1 (A) or forced swim 
in Experiment 2 (B) (mean ± SEM). MA-treated animals demonstrated increased corticosterone up to 72 h after the first 
dose compared to SAL-treated animals (A). Likewise, forced swim animals demonstrated increased corticosterone levels up to 
24 h (the last time point examined) after the beginning of the first swim (B). *p ≤ 0.05 vs SAL.BMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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Experiment-2
Forced swim, a potent stressor in rats, was employed to
determine if similar neurochemical markers were changed
after stress as was seen after MA treatment.
Temperatures and Body Weights
Body temperatures during FS could not be obtained
because of the animals being placed in water. There were
no differences in body temperatures between treatments
prior to FS testing (data not shown). Likewise, no differ-
ences in body weight were observed prior to FS (data not
shown).
Corticosterone
As with MA administration, plasma was collected at 1, 7,
and 24 h after the first of four 30 min forced swim sessions
that were initiated at 2 h intervals. Corticosterone, glu-
cose, and creatinine were assessed in the plasma. Plasma
corticosterone was significantly affected by FS, Treatment,
F(1, 41) = 111.40, p < 0.0001, and time of collection,
Time, p < 0.0001. An interaction of Treatment × Time,
F(2, 41) = 49.40, p < 0.0001, was also observed. At 1, 7,
and 24 h after the beginning of the first swim, corticoster-
one levels were increased in FS animals compared to con-
trol animals (Fig. 2B).
Glucose
There were significant effects of Treatment, F(1, 41) =
7.34, p < 0.01, Time, p < 0.01, and the interaction of Treat-
ment × Time, F(2, 41) = 5.36, p < 0.01. FS animals had sig-
nificantly decreased plasma glucose 7 h after MA
treatment compared to control animals; no differences in
glucose levels were observed at 1 or 24 h (Fig. 3B).
Creatinine
Levels of plasma creatinine were significantly altered by
FS, Treatment, F(1, 41) = 7.65, p < 0.01, Time (p <
0.0001), and the interaction of Treatment × Time, F(2, 41)
= 6.80, p < 0.01. FS animals showed decreased creatinine
compared to control animals at 1 and 7 h after the first
swim (Fig. 8A).
Creatine
As with animals that were treated with MA, the brains
were concurrently removed after plasma collection and
the hippocampus, neostriatum, prefrontal cortex, and cer-
ebellum (Fig. 8B–8E, respectively) were dissected for
examination of creatine and monoamines. For creatine,
there was a Treatment main effect in the cerebellum, F(1,
25) = 5.15, p < 0.05, but no effect of Time, or the Treat-
ment × Time interaction. FS animals showed decreased
levels of creatine in the cerebellum compared to control
animals (Fig. 8E inset). No differences were observed in
the hippocampus, neostriatum, or prefrontal cortex (Fig.
Glucose levels in plasma expressed as a percent of control following methamphetamine in Experiment 1 (A) or forced swim in  Experiment 2 (B) (mean ± SEM) Figure 3
Glucose levels in plasma expressed as a percent of control following methamphetamine in Experiment 1 (A) 
or forced swim in Experiment 2 (B) (mean ± SEM). Glucose levels were increased in MA-treated animals at 1 h follow-
ing the first dose compared to SAL-treated animals (A). Glucose levels were decreased in forced swim animals at 7 h following 
the first swim compared to control animals (B). *p ≤ 0.05 vs control, †p < 0.06 vs SAL.BMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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Creatinine levels in plasma (A), creatine levels in brain (B-E), and muscle creatine (F) of animals in Experiment 1 (mean ± SEM  expressed as a percent of control) Figure 4
Creatinine levels in plasma (A), creatine levels in brain (B-E), and muscle creatine (F) of animals in Experi-
ment 1 (mean ± SEM expressed as a percent of control). At 7 and 24 h, increases in creatinine were observed in MA-
treated animals; at 72 h, a decrease in creatinine was observed in MA-treated animals (A). No differences in brain creatine in 
MA-treated animals compared to SAL-treated animals were observed in the hippocampus (B), neostriatum (C), prefrontal cor-
tex (D), or cerebellum (E), at any of the time points examined. In addition, no differences were observed between MA-treated 
and SAL-treated animals in the levels of muscle creatine (F). * p ≤ 0.05 vs SAL.BMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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8B–D, respectively). Similarly, for creatine levels in the
gastrocnemius muscle, there were no significant effects of
FS (Fig. 8F).
Monoamines
There was no Treatment effect of FS on DA, 5-HT, or their
major metabolites in the neostriatum at 24 h (data not
shown). Neostriatum for 1 and 7 h were unavailable
because of a freezer malfunction. There was no effect of
Treatment on 5-HT levels in the hippocampus (Fig. 9A),
but there was a Time effect (p < 0.05). For 5-HIAA, there
were significant effects of Treatment, F(1, 41) = 12.76, p <
0.001, Time (p < 0.05), and the interaction of Treatment
× Time, F(1, 41) = 4.08, p < 0.05 (Control: 0.31 ± 0.03 ng/
mg tissue and FS: 0.43 ± 0.01 ng/mg tissue). 5-HIAA was
increased in FS animals compared to controls, although
this was significant only at the 7 h time point (Fig. 9B).
Adrenal and Thymus Weights
There were no significant effects of FS on either absolute
or percentage of body weight for adrenal or thymic
weights at any of the time points examined (Table 1).
Discussion
In the present experiments we compared the effects of MA
and forced swim on corticosterone, energy homeostasis,
and neurotransmitters to determine if the effects of MA
were unique to MA or if the effects could be characterized
as a general stress response. In this regard, both MA and
forced swim induced release of corticosterone from the
adrenal gland, however forced swim produced greater lev-
Monoamine levels in the neostriatum in Experiment 1 (mean ± SEM) Figure 5
Monoamine levels in the neostriatum in Experiment 1 (mean ± SEM). MA-treated animals demonstrated decreases 
in DA (A), DOPAC (B), 5-HT (C), and 5-HIAA (D). Decreases were not observed 1 h after the first dose but became evident 
following the last dose of the MA treatment. *p ≤ 0.05 vs SAL, †p < 0.07 vs SAL.BMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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els of corticosterone than MA. Interestingly, only MA pro-
duced reductions in the weights of the adrenal glands and
thymuses, even though forced swim had the larger effect
on corticosterone. Both MA and forced swim had effects
on glucose that were short-lived and time- and treatment-
dependent since increases were observed with MA while
decreases were observed with forced swim. Conversely, for
plasma creatinine, MA produced an increase during the
first 24 h, whereas a reduction was observed during at
least the first 7 h of forced swim. Forced swim induced
only a transient increase in 5-HIAA in the hippocampus,
however MA produced pronounced changes in monoam-
ines in the neostriatum and hippocampus. It appears that
the hippocampus may be more sensitive to the effects of
MA, since 5-HT in this region was already showing a
reduction in levels 1 h after a single dose. Although creat-
ine levels appeared slightly affected by MA, only forced
swim caused a significant change in creatine and only in
the cerebellum. Taken together, these data demonstrate
that MA has a unique profile of effects on hormone
release, glucose homeostasis, creatinine, and monoam-
ines that cannot be explained by a general stress response.
The hypothalamic-pituitary-adrenal (HPA) axis is a
homeostatic system activated by both psychological and
physiological stressors that induces a cascade of neuro-
transmitter and hormone release [18]. Not only is the
HPA axis activated during stress, it also participates in reg-
ulation of homeostatic processes such as digestion,
immune responses, and energy utilization [18]. HPA axis
activation ultimately leads to the release of glucocorti-
coids, namely corticosterone in the rat, which induces
Hippocampal monoamine levels in Experiment 1 (mean ± SEM) Figure 6
Hippocampal monoamine levels in Experiment 1 (mean ± SEM). MA-treated animals showed decreased 5-HT at 1, 7, 
24, and 72 h (A) and decreased 5-HIAA at 7, 24, and 72 h (B). *p ≤ 0.05 vs SAL.
GFAP levels 3 days following MA exposure by western blot  analysis (mean ± SEM) Figure 7
GFAP levels 3 days following MA exposure by west-
ern blot analysis (mean ± SEM). (A) GFAP was increased 
in MA-treated animals at 72 h following the first dose com-
pared to SAL-treated animals (From Left to Right: SAL, MA). 
(B) No difference in actin levels was observed (From Left to 
Right: SAL, MA). (C) GFAP/actin shown as a percent of con-
trol (SAL, n = 3, MA, n = 4). Open bar = SAL, black bar = 
MA. *p < 0.05 vs SAL.BMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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immediate responses such as increased availability of glu-
cose (via gluconeogenesis) and inhibition of immune,
reproductive, and digestive processes; all with the purpose
of facilitating the coping, adaptation, and recovery from
the stressor, although prolonged exposure can be detri-
mental [18-21]. In this study, we found similarities
between MA treatment and forced swim with regard to
corticosterone such that each treatment caused prolonged
activation of the adrenal gland. These data suggest that
other hormones of the HPA axis such as ACTH or cortico-
trophin-releasing factor should be examined in future
studies to determine if the long-term increases in corticos-
terone are a direct effect of MA on the adrenal or contin-
ued activation of the HPA axis. Considering the half-life of
MA in rats is approximately 1 h [22], the 72 h time point
exceeds the half-life by > 60 times, indicating that no
detectable MA would be present and suggesting that the
HPA axis is likely altered. These long-lasting alterations to
the adrenal glands, thymus, and corticosterone may indi-
cate a cumulative negative effect of MA or forced swim on
the regulation of many of stress-related components and
their receptive tissues ("allostatic load") [23]. In addition,
the alterations in corticosterone may represent a shift in
baseline levels that alters regulatory mechanisms and the
ability to maintain homeostasis during additional stres-
sors or change ("allostasis") [23]. Alternatively the pro-
longed corticosterone increase after the treatment period
may be the result of an altered circadian response, and
previous studies have demonstrated that MA treatment
can act as a zeitgeber and alter circadian rhythms [24].
However, it seems unlikely that changes in circadian pat-
terns alone could explain the long lasting elevation in cor-
ticosterone and this does not explain the increased levels
observed with forced swim. Investigation of a circadian
effect was outside of the scope of the present study.
Finally, since stress activates and modulates many other
physiological pathways and organs, such as the thyroid,
and these may also produce changes in learning and
memory, a profile of these hormones could provide useful
information. Likewise, the forced swim paradigm used
here might profitably be examined for its impact on learn-
ing and memory.
While both MA and FS produced large and protracted
increases in corticosterone, other measures were different
between the two experimental conditions. For example,
MA treatment resulted in an immediate increase (1 h) in
plasma glucose, while FS treatment caused opposite
effects, a decrease at 7 h. Others have also shown that MA
treatment increases glucose levels in fetal sheep up to 120
min after maternal administration [25]. The decrease in
glucose in FS animals was most likely due to the utiliza-
tion of available glucose during swimming, as levels
returned to baseline by 24 h. After MA treatment, creati-
nine levels in plasma were increased at 7 and 24 h, but
decreased at 72 h whereas after FS treatment they were
decreased at 1 and 7 h and returned to control levels by 24
h. The degradation of creatine to creatinine is a concentra-
tion-dependent, nonenzymatic process and plasma creat-
inine levels are often used as markers for kidney function
[16]. In this study, possibilities for increased creatinine
after MA administration would most likely be secondary
to rhabdomyolysis or renal dysfunction as has previously
been observed in human MA users [5]; however, renal
function was not evaluated in this study. While certain
effects observed in humans following MA were observed
in the present model, others, such as altered creatine in
the brain were not.
Creatine levels were not altered in MA-treated animals,
but FS-treated animals demonstrated an overall decrease
in creatine in the cerebellum, further demonstrating that
the effects of MA are not related to a general stress
response. The cerebellum is highly involved with motor
output and increased activity of this brain region during
FS may have resulted in the decreased creatine. While we
chose a stressor where muscle activity was present, FS is
likely to have exaggerated the motoric burden of the ani-
mals. It should be noted that altered brain creatine levels
in humans have been shown after long-term use and
abstinence from MA, whereas this study examined the
Table 1: Adrenal and thymus weights of animals receiving saline (SAL) or (+)-methamphetamine (MA) in Experiment 1 or weights 
from control animals or animals forced to swim (FS) in Experiment 2 (Mean ± SEM)
Tissue Treatment 1 h 7 h 24 h 72 h
Adrenal Gland (% Body Weight) SAL 0.186 ± 0.007 0.214 ± 0.007 0.194 ± 0.011 0.151 ± 0.007
MA 0.153 ± 0.008 0.187 ± 0.016 0.196 ± 0.014 0.168 ± 0.007
Control 0.130 ± 0.014 0.194 ± 0.015 0.182 ± 0.014 -
FS 0.151 ± 0.006 0.182 ± 0.011 0.188 ± 0.016 -
Thymus (% Body Weight) SAL 2.314 ± 0.084 2.263 ± 0.175 1.481 ± 0.108 1.361 ± 0.076
MA* 1.829 ± 0.125 2.041 ± 0.202 1.348 ± 0.084 0.9441 ± 0.071
Control 1.786 ± 0.212 2.174 ± 0.123 1.640 ± 0.100 -
FS 1.609 ± 0.129 2.057 ± 0.159 1.87 ± 0.075 -
*p < 0.05 vs SALBMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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Creatinine (A) levels in plasma, creatine levels in brain (B-E), muscle creatine (F) of animals in Experiment 2 (mean ± SEM  expressed as a percent of control) Figure 8
Creatinine (A) levels in plasma, creatine levels in brain (B-E), muscle creatine (F) of animals in Experiment 2 
(mean ± SEM expressed as a percent of control). Forced swim animals demonstrated decreased creatinine levels com-
pared to control animals at 1 and 7 h (A). No overall differences in creatine levels between forced swim and control animals 
were observed in hippocampus (B), neostriatum (C), or prefrontal cortex (D) In the cerebellum (E) there was a decrease in 
creatine (inset in E). No differences in muscle creatine levels were observed between forced swim and control animals (F). * p 
≤ 0.05 vs control.BMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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acute effects of MA; human studies on acute effects are
unknown. The present experiment did not evaluate the
levels of creatine in relation to other compounds such as
phosphocreatine or N-acetyl acetate that are obtained dur-
ing spectroscopy and therefore we cannot rule out that
changes in the ratio of these compounds might have
occurred. Nonetheless, others have shown that phospho-
creatine in the brain is unaltered following various doses
of (+)-amphetamine or (-)-MA [26-28].
MA treatment resulted in the expected astrogliosis as
shown by increased GFAP expression 72 h after treatment
in the neostriatum and decreased monoamines in the
neostriatum and hippocampus. Only a transient increase
in 5-HIAA was observed following forced swim. This pat-
tern is consistent with the well-described neurotoxic pro-
file of MA treatment [12,29-31]. Decreases in
monoamines were observed starting at 7 h after the first
dose of MA and remained decreased up to72 h. Most stud-
ies have examined the long-term effects of MA on
monoamine levels (3 days to months after treatment),
although striatal DA has previously been shown to be
depleted as early as 36 h after the first dose of repeated MA
treatment and tyrosine hydroxylase (TH) activity
decreased as early as 8 h after one 15 mg/kg dose of MA
[32]. The present data are the first to show reduced DA as
early as 7 h after the first dose. Tryptophan hydroxylase
(TPH) activity in the striatum has been demonstrated to
be decreased as early as 3 h after a single 10 mg/kg dose of
MA [33] and therefore, the reduction in TPH prior to
decreased 5-HT is consistent. Hippocampal 5-HT and 5-
HIAA have also been shown to be decreased as early as 36
h after the first dose of a repeated MA treatment [34].
Conclusion
These data provide verification that the treatment regimen
for MA used here was effective at inducing multiple indi-
ces of MA-induced neurotoxicity. Unlike human abusers,
creatine was unaltered in rats, although this may be
related to duration of use, since treatment was limited
here to a single day. Since humans show reductions in
monoamines after long-term use, an increase in creatinine
[5] and cortisol levels [4] during MA intoxication, the dos-
ing model used here appears to mimic certain effects
observed following human use and abuse. However, the
lack of effect on creatine suggests that longer exposure
periods in rats may be required to fully demonstrate the
effects observed in humans. A longer dosing period would
likely have effects on the behavioral consequences
observed in rats as well and should be the subject of future
investigations. Forced swim caused similar or even higher
increases in corticosterone than MA, yet did not induce
other changes similar to MA, indicating that the effects of
the drug are not attributable to its stress-like effects. Over-
all, the data suggest that MA induces a unique pattern of
effects that cannot be explained by a general stress phe-
nomenon. The present data provide a more complete pic-
ture of the short-term effects of MA and the similarities
and dissimilarities to multiple forced swims.
Hippocampal monoamine levels in Experiment 2 (mean ± SEM) Figure 9
Hippocampal monoamine levels in Experiment 2 (mean ± SEM). No overall differences in 5-HT levels between 
forced swim and control animals were observed (A). Forced swim animals demonstrated increased 5-HIAA levels compared to 
control animals at 7 h (B). *p ≤ 0.05 vs control.BMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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Methods
Animals and conditions
Male Sprague-Dawley rats (250–275 g; Charles River Lab-
oratories, Raleigh, NC) were allowed to acclimate to hous-
ing conditions (19 ± 1°C, 50 ± 10% humidity, and 14 h
light: 10 h dark cycle with lights on at 600 h) for 2 days
prior to either MA or forced swim treatment. Rats were
first housed in the colony room in pairs in cages measur-
ing 46 × 24 × 20 cm, but separated on the day of testing to
28 × 16 × 12 cm polycarbonate cages in a different room
maintained at an ambient temperature of 24°C during
drug or forced swim administration. Separation of ani-
mals was done to ensure a consistent environment rather
than have the potential for aggression when MA was
administered, especially since this would influence any
stress-related parameters. Food and water were provided
ad libitum except during treatment. All procedures were
conducted in accordance with the National Institutes of
Health Guidelines for the Care and Use of Laboratory Ani-
mals, and were approved by the Institutional Animal Care
and Use Committee of Cincinnati Children's Research
Foundation. The vivarium was accredited by the Associa-
tion for the Assessment and Accreditation of Laboratory
Animal Care (AAALAC).
Experiment-1
(+)-Methamphetamine-HCl (expressed as the freebase,
from the National Institute on Drug Abuse and greater
than 95% pure) or isotonic saline (SAL) was injected sub-
cutaneously to animals in 4 doses with a 120 min inter-
dose interval beginning at 900 h. Each dose consisted of
10 mg/kg in a volume of 3 ml/kg for a total daily dose of
40 mg/kg over the 6 h period. Each animal was weighed
prior to the first injection. For Experiment-1, the treat-
ment groups were MA and SAL and were run in two sepa-
rate cohorts. Four post-treatment time points were
assessed: 1, 7, 24, and 72 h after the first injection (n = 8,
8, 17, and 10, respectively). The 72 h time point was
included to demonstrate neurotoxicity with this dosing
regimen, although it was the early time points that were of
interest. Injections of both MA and SAL were delivered in
the dorsum and injection sites were varied to prevent skin
irritation.
Experiment-2
Forced swim has previously been demonstrated to
increase corticosterone levels more than other stressors
[17]. Forced swim for 30 min was performed by placing
each rat in a 15 cm (diameter) by 46 cm tall PVC cylinder
filled with 35 cm of water (22 ± 1°C) either once or four
times; as with MA treatment. FS was administered begin-
ning at 900 h for the single stress group and beginning at
900 h × 4 at 2 h intervals for the multiple FS group. Ani-
mals were weighed prior to the beginning of the FS regi-
men. Three time points were examined: 1, 7, and 24 h
after the beginning of the first FS. Group sizes were FS = 8,
control = 8 for each of the 3 time points, or 48 animals
total. Between FS trials, all animals were maintained in 28
× 16 × 12 cm polycarbonate cages in a separate room from
the colony, exactly as in Experiment-1.
Body Temperature
On the day of arrival, animals were lightly anesthetized
with isofluorane and injected with implantable tempera-
ture transponders (IPTT-300: Bio Medic Data Systems,
Seaford, DE). The subcutaneous probes were used to alle-
viate the hyperthermia and stress of rectal temperature
measurements during dosing [35] and the physical
manipulation of the animal that occurs with such record-
ings. Previous data have demonstrated that handling and
rectal temperature measurements increase corticosterone
and body temperature [36].
During the period of MA or FS treatment, body tempera-
tures were monitored every 30 min beginning with the
first treatment and for the next 8 h. In order to prevent
excessive hyperthermia during MA treatment, a cooling
protocol was followed. If an animal's temperature reached
40°C it was placed in a shallow bath of room temperature
water and its temperature was then monitored every 5–10
min. Once an animal's temperature fell below 40°C it was
removed from the water and returned to its holding cage.
After 8 h (2 h after the last dose), animals were returned
to the colony room. A comparison of cooled animals ver-
sus non-cooled animals demonstrated that cooling did
not significantly attenuate the depletions in monoamines.
Body weight
Animals were weighed on the day of drug or FS adminis-
tration prior to the first treatment. For experiment-1, ani-
mals were also weighed 24, 48, and 64 h after MA dosing.
Tissue collection
At the designated time points, animals were transported
individually to an adjacent suite (< 30 s after removal
from cage), decapitated [37], and blood collected in poly-
ethylene tubes (12 × 75 mm) containing 2% EDTA (0.05
ml/tube). The brain was rapidly removed, placed over ice,
and the neostriatum and hippocampus were dissected as
described previously [38] as well as the prefrontal cortex
and cerebellum. All tissues were frozen on dry ice and
stored at -80°C until assayed.
The adrenal glands and thymus from each animal were
removed, freed of fatty tissue, and weighed. The data for
tissue were expressed as absolute tissue weight or as a per-
centage of body weight. For experiments-1 and 2, initial
body weights for percentage of body weight analysis were
utilized except for experiment-1 the 64 h body weight was
used for the 72 h time point. These tissues were collectedBMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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since they are known to be affected by hormones of the
HPA axis, particularly during increased activation of this
pathway [39-42].
Corticosterone, creatinine and glucose determinations
Blood was collected in ice-chilled polypropylene tubes
containing EDTA, centrifuged at 4°C for 15 min, plasma
aliquoted, and stored at -80°C until assayed for corticos-
terone and creatinine (Crn). For the assessment of corti-
costerone, plasma was diluted 5:1 in assay buffer and
assayed in duplicate using a commercially available EIA
kit for corticosterone (IDS, Fountain Hills, AZ). Glucose
in whole blood was determined using a commercially
available glucometer (Precision Xtra, Abbott Laboratories,
Bedford, MA).
For creatinine, 300 μl of methanol were added to 100 μl
of plasma in microcentrifuge tubes, vortex-mixed for 1
min, and centrifuged at 9,400 × g for 10 min. The super-
natant was transferred to an autosampler vial, and 50 μl
was automatically injected into a high pressure liquid
chromatography (HPLC) system. A Rainin Microsorb-MV
reversed-phase column (4.6 mm × 15 cm, 5-μm bead size)
was used. The mobile phase consisted of potassium phos-
phate monobasic (40 mmol/l), sodium dodecyl sulfate
(10 mmol/l), 190 ml methanol, and 180 ml acetonitrile
(adjusted to a pH of 3 with phosphoric acid). The flow
rate was 0.9 ml/min and the retention time for creatinine
and cimetidine (internal standard) were 6.9 min and 11.4
min, respectively. The absorbance detector was set at 236
nm. The analysis was run at 30°C.
Creatine assessment
Free creatine was measured in the gastrocnemius muscle
and in several brain regions including: cerebellum, neos-
triatum, prefrontal cortex, and hippocampus. Gastrocne-
mius muscle was chosen because MA-treated animals
display hyperactivity and FS induces vigorous paddling,
both behaviors require the use of the gastrocnemius mus-
cle. Free creatine was measured using a fluorimetric tech-
nique described previously [43] with modification.
Briefly, this method combines ninhydrin, at alkaline pH,
with guanidine, and monosubstituted guanidines to form
a fluorescent product that is specific for creatine. The assay
has an effective range from 1.0 × 10-7 M to 2.5 × 10-5 M.
The creatine standard was made from reagent grade creat-
ine (MP Biomedicals, Inc.). Each sample was weighed and
200 μl of RIPA (50 mM Tris, 1% NP-40, 25% Na-deoxy-
cholate, 150 mM NaCl, 1 mM EDTA, Na3VO4, 1 mM NaF
along with 1 μg/ml of each: aprotinin, leupeptin, pepsta-
tin) for each 100 mg of tissue was added prior to tissue
homogenization. Homogenates were heated for 5 min at
103°C and then centrifuged at 32,091 × g (4°C) for 10
min. The supernatant was then collected.
Creatine determination involved adding 120 μl of the
supernatant with 240 μl of Ba(OH)2 and 240 μl of ZnSO4.
After the formation of a precipitate the samples were cen-
trifuged at 32,091 × g (4°C) for 3 min. A total of 150 μl of
the supernatant was placed in a 96-well, black-bottomed
plate (ISC Bioexpress) and each sample was run in tripli-
cate. Ninhydrin (75 μl) was added to each well while
keeping the plate protected from external light during and
after the addition of 75 μl of KOH. Eight min following
the addition of the KOH, the plate was read using a fluor-
imeter (Spectramax M2; Molecular Devices) at an absorb-
ance of 410 nm excitation and 525 nm emission.
Flourimetric readings were recorded and creatine concen-
trations were calculated from standard curves generated
from each plate and expressed as μmol/mg tissue.
Monoamine assessment
Brain tissue concentrations of dopamine (DA), 3,4-dihy-
droxyphenylacetic acid (DOPAC), serotonin (5-HT), and
5-hydroxyindolacetic acid (5-HIAA) in the neostriatum
and 5-HT and 5-HIAA in the hippocampus were quanti-
fied using HPLC with electrochemical detection as
described previously [44]. Tissues were homogenized in
50 volumes of 0.2 M perchloric acid and centrifuged for 6
min at 10,000 × g. Aliquots of 20 μl were injected onto a
C18-column (MD-150, 3 × 150 mm; ESA, Chelmsford,
MA) connected to either a LC-4B amperometric detector
(Bioanalytical Systems, West Lafayette, IN) or a Coulo-
chem (25A, Chemsford, MA) detector and an integrator
recorded the peak heights that followed each injection.
The potential for the LC-4B was 0.6 V and the potentials
of E1 and E2 on the analytical cell (model 5014B) of the
Coulochem were -150 and -160 mV, respectively and Ag/
AgCl reference electrodes were used. The mobile phase
consisted of 35 mM citric acid, 54 mM sodium acetate, 50
mg/l of disodium ethylenedeamine tetraacetate, 70 mg/l
of octanesulfonic acid sodium salt, 6% (v/v) methanol,
6% (v/v) acetonitrile, pH 4.0, and pumped at a flow rate
of 0.4 ml/min. Quantities of the analytes were calculated
on the basis of known standards. Retention times for
DOPAC, DA, 5-HIAA, and 5-HT were approximately 3.0,
5.0, 7.0, and 20.0 min, respectively.
GFAP Analysis
Neostriata from Experiment-1 (72 h) were homogenized
in cold RIPA buffer. Protein concentrations were deter-
mined using Pierce BCA Protein Assay Reagent Kit (Rock-
ford, IL) according to the manufacturer's specifications
and homogenates were diluted to a concentration of 1 μg
protein/ml with PBS. Samples (10 μl) were diluted 1:1
with 2× loading buffer, boiled for 5 min and loaded on 8–
16% polyacrylamide gels (ISC BioExpress, Kaysville, UT)
with control and experimental animals equally distrib-
uted on each gel. Proteins separated by electrophoresis
were transferred in a buffer of 25 mM bicine, 20 mM Tris,BMC Neuroscience 2008, 9:49 http://www.biomedcentral.com/1471-2202/9/49
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and 10% MeOH at 40 V for 1.5 h to Immobilon-PVDF
membranes (Millipore, Bedford, MA). Membranes were
blocked by incubating at 4°C with 3% BSA in PBS with
0.1% Tween-20 (PBST) overnight to prevent nonspecific
binding of antibodies. Membranes were then incubated
for 1 h with a 1:500 dilution of GFAP (Fitzgerald, Con-
cord, MA) or actin (Chemicon International, Temecula,
CA) antibody. Following washing (3 × 5 min with PBST),
membranes were incubated for 30 min at room tempera-
ture with 1:5000 dilution of goat anti-mouse conjugated
to alkaline phosphatase for both GFAP and actin. Mem-
branes were washed (3 × 5 min with PBS), followed by
incubation with CDP Star chemiluminescent (KPL, Gaith-
ersburg, MD) substrate for 5 min. Membranes were
exposed to film until adequate signal development was
achieved; films were then scanned and protein bands were
quantified using ImageJ software (NIH, Bethesda, MD).
The density of the GFAP or actin band of the treated sam-
ples was divided by the density of the control sample in
each gel and GFAP values were divided by actin values to
control for protein concentration for each sample.
Data Analysis
Data were analyzed using factorial analysis of variance
(ANOVA), general linear model (GLM; SAS Institute,
Cary, NC) or t-tests (GFAP only). Treatment (MA or SAL,
Exp-1; FS or Naïve, Exp-2) and Time (1, 7, 24, or 72 h)
were between-subject factors. Significance was set at a
level of p ≤ 0.05. Data are presented as group means ±
SEM.
Abbreviations
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